Develops CAR-T cell therapies for cancer treatment. Conducts clinical trials for innovative oncology therapies. Now — the numbers.
This is an established company with proven profits.
Red columns mark years that ended in a loss.
If every debt were paid off today, $2.0M would still be left in the vault — a solid cushion for hard times.
The market pays 13× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $2.0M in the vault; even if every debt were paid off, $2.0M would remain.
The stock sits at $0.28. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The sales tempo runs behind the sector. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.